

SPEAKER AND AUTHOR DISCLOSURES

The American Society of Human Genetics (ASHG) and The Federation of American Societies for Experimental Biology (FASEB) require that audiences at educational programs sponsored by ASHG and FASEB be informed of a presenter's (i.e., speaker's, faculty member's, author's, and contributor's) academic and professional affiliations, and the disclosure of the existence of any significant financial interest or other relationship a presenter has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. This policy allows the listener/attendee to be fully knowledgeable in evaluating the information being presented.

Disclosure includes any relationship that may bias one's presentation or which, if known, could give the perception of bias. These situations may include, but are not limited to:

- | | | |
|---|--|--|
| <ol style="list-style-type: none"> 1. stock options or bond holdings in a for-profit corporation or self-directed pension plan 2. research grants 3. employment (full or part-time) 4. ownership or partnership | <ol style="list-style-type: none"> 5. consulting fees or other remuneration 6. non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson 7. receipt of royalties | <ol style="list-style-type: none"> 8. speakers' bureau 9. inventor/patent owner 10. advisor 11. collaboration 12. company owner |
|---|--|--|

Following is an alphabetical list of invited session speakers and first/presenting authors of abstracts who have disclosed one or more such relationships, and names of companies with which those relationships exist. The number following each company name represents the specific relationship from the list above. Session and/or abstract program numbers appear in parentheses. If a presenter is not listed, there are no relationships to disclose. Additional information may be obtained from FASEB by contacting P. McGovern at mcgovern@faseb.org.

<p>Abraham, R., Celera Diagnostics - 11, 5 (2103)</p> <p>Acton, R., National Heart Lung and Blood Institute, NIH - 3 (1482)</p> <p>Alonso-Alegre, S., Progenika - 2 (1036)</p> <p>Antonarakis, S. E., Affymetrix - 3 (106)</p> <p>Arn, P., Genzyme - 6 (736)</p> <p>Bacanu, S., GSK - 3 (2284)</p> <p>Ballif, B. C., Signature Genomic Laboratories, LLC - 3 (43)</p> <p>Beck, M., Shire Human Genetic Therapies - 2, 5, 10 (1362)</p> <p>Bell, D., Applicant on a patent describing EGFR mutations - 7, 9 (Session 46)</p> <p>Bennett, R. R., Applied Biosystems Inc. - 11 (1851)</p> <p>Bibikova, M., Illumina, Inc. - 1, 3 (142)</p> <p>Bronnikov, D., GenoLogics Life Sciences Software Inc. - 3 (1267)</p> <p>Brown, C., Applied Biosystems - 3 (1241); Solexa Inc. - 3 (1268)</p> <p>Burton, B. K., Biomarin Pharmaceutical Inc. - 2 (2332)</p> <p>Chakravarti, A., Affymetrix - 10 (Session 9)</p> <p>Chen, S., Applied Biosystems - 3 (1245)</p> <p>Clancy, K. P., Invitrogen Corp - 1, 3 (1270)</p> <p>Clarke, J., Shire Human Genetic Therapies, Inc. - 2, 5, 8 (2375)</p> <p>Coleman, H., Genelex Corp - 1, 3, 4 (Session 7)</p> <p>Conley, Y., submitted application for patent - 9 (1657)</p> <p>Coppinger, J., Signature Genomic Laboratories - 3 (135)</p> <p>Corzo, D., Genzyme Corporation - 3 (58)</p> <p>Cushing, T. H., Ucylyd Pharma, Inc. - 5 (2333)</p> <p>David, D. A., Idaho Technology - 3, 4, 9 (1204)</p> <p>Deegan, P. B., Shire Human Genetic Therapies - 2, 8; Genzyme Corporation - 2, 8 (1330)</p> <p>De La Vega, F. M., Applied Biosystems - 1, 3, 9 (1589)</p> <p>De Witte, A., Agilent Technologies, Inc. - 3 (294)</p> <p>Dickson, P., Biomarin Pharmaceutical - 5; Genzyme - 5 (2351)</p> <p>Dong, L., Genzyme Genetics - 1, 3 (862)</p> <p>Edmunds, T., Genzyme - 3 (2376)</p> <p>Ehm, M. G., GlaxoSmithKline - 1, 3 (1976)</p> <p>Eichler, E., Agilent - 11; NimbleGen - 11 (Session 5)</p> <p>Enns, G. M., Ucylyd Pharma, Inc. - 5 (2382)</p> <p>Fagin, J. A., Astra Zeneca - 10; Novartis - 2 (Session 52)</p> <p>Fairley, C., Genzyme Corp - 2, 5, 6, 8, 10 (1383)</p> <p>Fan, J., Illumina, Inc. - 1, 3 (41)</p> <p>Feinberg, A. P., NIH - 2; March of Dimes - 2; Doris Duke Charitable Foundation - 2; Dana Foundation - 2 (Session 22)</p> <p>Finnell, R. H., PamLabs - 10; Glaxo - 10 (Session 3)</p> <p>Fyfe, J. C., National Institutes of Health - 2 (882)</p> <p>Giampietro, P., Samuel A. Seaver Foundation - 2 (1431)</p> <p>Godiska, R., Lucigen Corp. - 3 (1237)</p> <p>Goin-Kochel, R. P., NICHD - 2; NIMH - 2; Carman Trust Award for Scientific Research - 2 (1708)</p>	<p>Goldstein, D., GSK - 2; J&J - 5 (Session 6); GSK - 2; J&J - 5 (Session 46)</p> <p>Goldstein, D. B., GSK - 2; J&J - 5 (Session 2)</p> <p>Grabowski, G., Genzyme Corp - 2, 5, 6, 8 (2352)</p> <p>Grace, M. E., Genzyme - 2, 5, 7; Amicus - 1, 5 (1320)</p> <p>Hockett, R., Eli Lilly - 1, 3 (1169)</p> <p>Horner, S. A., Signature Genomic Laboratories, LLC - 3 (38)</p> <p>Huang, D., Quest Diagnostics Inc. - 3 (1164)</p> <p>Hunkapiller, K., Applied Biosystems - 3, 1 (1308)</p> <p>Hyland, F. C. L., Applied Biosystems - 3 (89)</p> <p>Jackson, A. P., MRC Technology - 9 (148)</p> <p>Jacobs, S., Affymetrix, Inc. - 3 (1279)</p> <p>Johnson, K. L., Spectral Genomics - 11 (2016)</p> <p>Jonsson, J. J., BioCule Inc. - 1, 4 (1233)</p> <p>Kelly, E. D., Hitachi Europe Ltd. - 3 (2323)</p> <p>Kent, W. J., Affymetrix - 1 (1280)</p> <p>Kilpatrick, M. W., Ikonisys Inc. - 1, 3 (2013)</p> <p>Kishnani, P., Genzyme - 2, 10 (675)</p> <p>Knowles, M. R., North Carolina Center for Biotechnology - 2 (1815)</p> <p>Kuhn, K., Illumina, Inc. - 3 (1235)</p> <p>Lakdawalla, A., Applied Biosystems - 3 (937)</p> <p>Lammer, E. J., Roche Molecular Systems - 11 (Session 3)</p> <p>Levy, H., BioMarin Pharmaceuticals, Inc. - 5, 11 (Session 28); BioMarin Pharmaceutical, Inc. - 5, 11 (57)</p> <p>Li, K., Applied Biosystems - 12 (1176)</p> <p>Lince, D. H., TorreyPines Therapeutics - 1, 3 (1225)</p> <p>Ling, H., GSK - 2; GSK - 3 (1522)</p> <p>Maegawa, G., Actelion Pharmaceuticals Canada Inc. - 2 (2341)</p> <p>Martin, R., Shire Human Genetic Therapies, Inc. - 2, 5 (1331)</p> <p>McCoy, M., Genzyme - 3 (1998)</p> <p>McDonald, E. N., Genzyme Genetics - 3 (805)</p> <p>McEachern, K., Genzyme Corp - 3 (2336)</p> <p>McGrath, P., One Cell Systems, Inc. - 1, 2, 3, 4 (303)</p> <p>Meade, M. C., Axial Biotech, Inc. - 1, 3, 4 (1662)</p> <p>Milos, P., Pfizer Inc - 1, 3 (Session 9)</p> <p>Molouki, A., Roche Applied Science - 3 (1100)</p> <p>Murray, S. S., Illumina - 1, 3 (75)</p> <p>Nelson, L. M., Axial Biotech, Inc. - 1, 3, 4 (1531)</p> <p>Nygren, A. O. H., MRC-Holland BV - 3 (938)</p> <p>Oglesbee, D., Mayo Clinic - 3, 9 (1379)</p> <p>O'Leary, E., One Cell Systems, Inc. - 1, 2, 3, 4 (755)</p> <p>Palomaki, G., Quest Diagnostics Nichols Institute - 2 (2027)</p> <p>Peiffer, D. A., Illumina - 1, 3 (1182)</p> <p>Pettersson, F., GlaxoSmithKline - 2 (1580)</p> <p>Phillips, M. S., Autogenomics, Inc. - 5, 10, 11 (1170)</p> <p>Pirozhenko, A., Invitrogen Corp - 1, 3 (1978)</p> <p>Pouresmaeili, F., Shahid Beheshti University of Medical Sciences - 2, 3 (1730)</p>	<p>Price, A. L., Millennium Pharmaceuticals - 5 (252)</p> <p>Probst, F. J., Baylor College of Medicine - 3 (845)</p> <p>Pryor, R. J., Idaho Technology - 11 (1251)</p> <p>Puffenberger, E., Affymetrix, Inc. - 11 (Session 4)</p> <p>Raelson, J., Genizon Biosciences - 3, 4, 9 (1534)</p> <p>Ranade, K., Bristol-Myers Squibb - 3 (1964)</p> <p>Reed, G. H., Idaho Technology - 1 (331)</p> <p>Rich, S. S., NIH, NIDDK (DK062418) - 2 (Session 10)</p> <p>Roberts, D. N., Agilent Technologies, Inc. - 3 (311)</p> <p>Rubinstein, W. S., Myriad Genetic Laboratories, Inc. - 8 (188)</p> <p>Sadovnick, A., Teva Neuroscience - 2, 8; Berlex Canada - 2, 8 (1125)</p> <p>Sakul, H., Pfizer, Inc. - 3 (2149)</p> <p>Samaha, R. R., Applied Biosystems - 1, 3 (481)</p> <p>Santa Rosa, A. A. P., Genzyme Corporation - 11 (1412)</p> <p>Scrifer, C. R., BioMarin CA - 5, 10, 11; Scripps Institute (Stevens' Lab) - 11 (Session 28)</p> <p>Sekhon, G. S., Genzyme Genetics - 3 (1995)</p> <p>Selzer, R. R., NimbleGen Systems, Inc. - 1, 3 (826)</p> <p>Sims, K. B., Genzyme Corporation - 5, 8, 10 (2356)</p> <p>Song, S., Agilent Technologies - 3 (1183)</p> <p>Steiner, R. D., Genzyme, - 5, 10; Biomarin, Shire, Actelion - 5 (Session 8)</p> <p>Stenberg, D. M., Genzyme Genetics - 3 (2014)</p> <p>Su, X., NIH Grant #U01 HL069757 - 2 (1735)</p> <p>Sutton, V. R., Baylor College of Medicine Medical Genetics Laboratories - 3 (46)</p> <p>Swanson, M., AGTC - 9 (Session 26)</p> <p>Tafas, T., Ikonisys Inc - 1, 3, 4, 9 (856)</p> <p>Tan, R., Applied Biosystems - 3 (927)</p> <p>Tian, C., Perlegen Systems - 11 (2204)</p> <p>Tsai, J., Genzyme Genetics - 3 (319)</p> <p>Tsalenko, A., Agilent Technologies - 1, 3 (320)</p> <p>Van den Veyver, I., Baylor College of Medicine - 1 (50)</p> <p>Vassar-Nieto, D., Sigma-Aldrich Research Biotech - 3 (1255)</p> <p>Waisbren, S. E., Biomarin - 3, 5 (1415)</p> <p>Waldek, S., Genzyme Corporation - 2, 5 (2358)</p> <p>Wang, Y. K., Affymetrix - 3 (1256)</p> <p>Ward, K., Axial Biotech, Inc. - 1, 3, 4 (1663)</p> <p>Wei, D., Montefiore Medical Center - 3 (325)</p> <p>Wenstrup, R., Genzyme Corp - 2, 5, 6 (2329)</p> <p>Wenz, M., Applied Biosystems - 3 (1107)</p> <p>Wilcox, W. R., Genzyme Corp - 2, 5, 8, 10 (1341)</p> <p>Wokke, J., Genzyme Corporation - 10 (1357)</p> <p>Wyatt, P., Quest Nichols Laboratory - 2 (2011)</p> <p>Yu, J., NimbleGen Systems, Inc. - 3, 11 (874)</p> <p>Zariwala, M. A., North Carolina Center for Biotechnology - 2 (1163)</p> <p>Zimmer, R., R. Zimmer - 3 (1877)</p> <p>Zimran, A., Shire Human Genetic Therapies, Inc. - 5 (2359)</p>
---	---	--